HOME > ARCHIVE
ARCHIVE
- \18.9 Bil. to Promote Science and Tech-nology: Korosho Supplementary Budget
January 13, 2003
- Meet the Leaders (14)
January 13, 2003
- METI Draft Budget Includes \19.2 Billion for Life Sciences
January 13, 2003
- FY2003 Budget Includes \3,587.6 Bil. for Science, Technology
January 13, 2003
- Most of Monkasho's Budget Demands Related to Life Science Rejected by MOF
January 13, 2003
- Outside Board Members Should Be Increased: JIC
January 13, 2003
- REGULATORY NEWS IN BRIEF
January 13, 2003
- Bungyo Rate Up 4.3 Points to 47.7% in 1st Half of FY2002
January 13, 2003
- Drugs Account for 22.5% of Total Medical Costs
January 6, 2003
- Putting Patients First - 21st Century Health Care in Japan
January 6, 2003
- Preferential Taxation System for R&D to Be Expanded
January 6, 2003
- Proposed List of Bio-derived Products Includes 183 Active Ingredients or 944 Products
January 6, 2003
- Fundamental Reform Needed to Achieve Patient-oriented Healthcare System
January 6, 2003
- Domestic Drug Production Rose 5.2% to \6.5 Trillion in 2001
January 6, 2003
- A New Horizon, A New Prospective
January 6, 2003
- Korosho Reports Self-assessment of Its Own Policies
January 6, 2003
- Learning from the Last Decade and Making Use of the Learning in the Next Decade
January 6, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 6, 2003
- 2003: Integration to Disintegration
January 6, 2003
- BULLETIN
January 6, 2003
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
